Interest in modulating the immune response beyond glucocorticoids has existed since the COVID-19 pandemic began. Recent trials have shown promising results with IL-6 inhibitors such as tocilizumab although similar data on Sarilumab is lacking. In this report, we analyze the current evidence on Sarilumab in hospitalized COVID-19 patients to evaluate its efficacy.
It is said that no discovery is complete until its implications have been fully realized. The identification of a previously unrecognized phenomenon says little of its potential effects. What appears as a stroke of good luck can culminate in disaster; misfortune may harbor unimagined potential. Discovery is a double-edged sword that manifests only over time.
Antibiotic drugs are the most frequently prescribed medications among hospitalized patients for life-saving purposes, mainly in immunocompromised patient, like in patient with end stage renal disease on hemodialysis (HD) or those who had documented bacterial infection.
The Department of Internal Medicine publishes peer-reviewed, open access online papers that focuses on general and internal medicine. Clinical studies in all areas of human disease and medicine are accepted for publication.
The Department is committed to publish high-quality papers and to promote improved patient care, research, and education in primary care, general internal medicine, and hospital medicine. The specific topics covered by Department of Internal Medicine include but not limited to:
The Editors actively encourages Clinical aspects of basic research and trials that will have an impact on the understanding of health and disease. Case reports, focused research on a broad range of disciplines as well as experimental papers may be submitted. Besides, authors may contribute short reviews (by invitation from the Editor) and letters to the editor. This journal adheres to the policies recommended by The Committee on Publication Ethics (COPE).
Please direct any enquiry or submit papers to: email@example.com